METASTATIC TRIPLE-NEGATIVE BREAST CARCINOMA
Clinical trials for METASTATIC TRIPLE-NEGATIVE BREAST CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new METASTATIC TRIPLE-NEGATIVE BREAST CARCINOMA trials appear
Sign up with your email to follow new studies for METASTATIC TRIPLE-NEGATIVE BREAST CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Custom-Made vaccine takes on tough breast cancer
⭐️ VACCINE ⭐️ Recruiting nowThis early-stage study tests a personalized vaccine made from a patient's own tumor, combined with immunotherapy drugs, for triple negative breast cancer. The goal is to see if the vaccine is safe and can help the immune system attack cancer cells. About 18 adults with various st…
Matched conditions: METASTATIC TRIPLE-NEGATIVE BREAST CARCINOMA
Phase: PHASE1 • Sponsor: Emory University • Aim: ⭐️ VACCINE ⭐️
Last updated May 26, 2026 03:14 UTC
-
New vaccine shows promise in fighting Hard-to-Treat breast cancer
⭐️ VACCINE ⭐️ Recruiting nowThis study tests a vaccine called STEMVAC, given with chemotherapy, for people with a type of advanced breast cancer (triple-negative) that has spread. The vaccine is designed to train the immune system to attack cancer stem cells. About 20 adults with PD-L1 negative tumors will …
Matched conditions: METASTATIC TRIPLE-NEGATIVE BREAST CARCINOMA
Phase: PHASE2 • Sponsor: University of Washington • Aim: ⭐️ VACCINE ⭐️
Last updated May 22, 2026 14:04 UTC
-
Could a parasite drug boost cancer immunotherapy? new trial tests ivermectin combo
Disease control Recruiting nowThis study tests whether adding ivermectin (a common parasite drug) to standard immunotherapy can help shrink tumors in people with metastatic triple-negative breast cancer. About 34 adults whose cancer has spread will receive the combination. The goal is to find the best dose an…
Matched conditions: METASTATIC TRIPLE-NEGATIVE BREAST CARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: Yuan Yuan • Aim: Disease control
Last updated May 26, 2026 03:21 UTC
-
New drug cocktail targets Hard-to-Treat HER2 cancers
Disease control Recruiting nowThis early-stage trial tests the safety and best dose of combining two drugs—pidnarulex and trastuzumab deruxtecan—in people with advanced breast cancer or other solid tumors that have a protein called HER2. The study includes up to 36 adults whose cancer has spread, cannot be re…
Matched conditions: METASTATIC TRIPLE-NEGATIVE BREAST CARCINOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 26, 2026 03:20 UTC
-
New vaccine combo aims to boost immune attack on Hard-to-Treat breast cancer
Disease control Recruiting nowThis study tests whether adding a personalized vaccine (neoantigen vaccine) to a standard chemo-immunotherapy combination helps control metastatic triple-negative breast cancer better than the combination alone. About 70 adults with this aggressive, advanced breast cancer will re…
Matched conditions: METASTATIC TRIPLE-NEGATIVE BREAST CARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 26, 2026 03:15 UTC
-
New hope for tough breast cancer: early trial combines three drugs to fight tumors
Disease control Recruiting nowThis early-stage trial tests a new drug called ASTX727 alongside standard chemotherapy (paclitaxel) and immunotherapy (pembrolizumab) for people with metastatic triple-negative breast cancer that cannot be removed by surgery. The goal is to find the safest dose and see if the com…
Matched conditions: METASTATIC TRIPLE-NEGATIVE BREAST CARCINOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 26, 2026 03:15 UTC
-
New triple-drug attack aims to shrink hard-to-treat breast cancer
Disease control Recruiting nowThis early-phase trial tests whether adding an experimental drug (ZEN003694) to standard chemotherapy and immunotherapy is safe for people with advanced triple-negative breast cancer that has spread. About 57 participants will receive the combination to find the best dose and che…
Matched conditions: METASTATIC TRIPLE-NEGATIVE BREAST CARCINOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 26, 2026 03:12 UTC
-
New drug combo targets Hard-to-Treat breast cancer in early trial
Disease control Recruiting nowThis early-phase trial tests whether combining two drugs, neratinib and ruxolitinib, is safe and can shrink tumors in people with metastatic triple-negative breast cancer that has come back in the chest wall after chemotherapy. About 20 women aged 18 or older will take both pills…
Matched conditions: METASTATIC TRIPLE-NEGATIVE BREAST CARCINOMA
Phase: EARLY_PHASE1 • Sponsor: Baylor Research Institute • Aim: Disease control
Last updated May 26, 2026 03:12 UTC
-
Freeze and fight: new combo tackles tough breast cancer
Disease control Recruiting nowThis early-phase trial tests whether freezing a tumor (cryoablation) can boost the immune system's response to the drug pembrolizumab in people with advanced triple-negative breast cancer. About 30 participants will either receive the combination or pembrolizumab alone. The goal …
Matched conditions: METASTATIC TRIPLE-NEGATIVE BREAST CARCINOMA
Phase: PHASE1 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated May 26, 2026 03:03 UTC
-
Custom-Made cancer vaccine shows promise in advanced tumors
Disease control Recruiting nowThis study tests a personalized vaccine made from a patient's own tumor proteins, combined with the immunotherapy drug pembrolizumab, for people with advanced solid tumors (like breast, lung, or skin cancer). The goal is to see if the combination is safe and helps the immune syst…
Matched conditions: METASTATIC TRIPLE-NEGATIVE BREAST CARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated May 22, 2026 14:04 UTC
-
New combo attack on hard-to-treat breast cancer shows promise in early trial
Disease control Recruiting nowThis study tests whether adding high-dose radiation to standard immunotherapy (pembrolizumab) and chemotherapy can help people with a specific type of advanced breast cancer (PD-L1 positive, triple-negative) that has spread. About 29 participants will receive this combination to …
Matched conditions: METASTATIC TRIPLE-NEGATIVE BREAST CARCINOMA
Phase: PHASE2 • Sponsor: Emory University • Aim: Disease control
Last updated May 22, 2026 14:03 UTC
-
New vaccine combo aims to shrink breast cancer brain tumors
Disease control Recruiting nowThis study tests a combination of two treatments for people with breast cancer that has spread to the brain. One is a vaccine made from the patient's own immune cells, designed to help the body recognize and attack cancer. The other is a drug called pembrolizumab, which helps the…
Matched conditions: METASTATIC TRIPLE-NEGATIVE BREAST CARCINOMA
Phase: PHASE2 • Sponsor: Roswell Park Cancer Institute • Aim: Disease control
Last updated May 20, 2026 11:55 UTC
-
Promising combo targets Hard-to-Treat breast cancer
Disease control Recruiting nowThis study tests whether adding tamoxifen to a standard chemotherapy drug (liposomal doxorubicin) can shrink tumors in people with advanced triple-negative breast cancer that has spread or cannot be removed by surgery. About 30 adults who have already tried at least two other tre…
Matched conditions: METASTATIC TRIPLE-NEGATIVE BREAST CARCINOMA
Phase: PHASE2 • Sponsor: Roswell Park Cancer Institute • Aim: Disease control
Last updated May 18, 2026 12:04 UTC
-
App-Based monitoring aims to boost quality of life in advanced breast cancer
Symptom relief Recruiting nowThis study tests whether a digital platform called CUREETY TECHCARE can improve quality of life and reduce hospital visits for people with metastatic triple-negative breast cancer starting their first treatment. About 472 participants will either use the app to report symptoms an…
Matched conditions: METASTATIC TRIPLE-NEGATIVE BREAST CARCINOMA
Phase: NA • Sponsor: UNICANCER • Aim: Symptom relief
Last updated May 18, 2026 12:14 UTC
-
Real-World data sought on powerful breast cancer drugs
Knowledge-focused Recruiting nowThis study is tracking 100 people with HER2-negative metastatic breast cancer who are receiving antibody-drug conjugates (ADCs) as part of their normal care. Researchers want to see how long these drugs control the cancer in real-world settings. The goal is to gather information …
Matched conditions: METASTATIC TRIPLE-NEGATIVE BREAST CARCINOMA
Sponsor: University of California, San Francisco • Aim: Knowledge-focused
Last updated May 26, 2026 03:12 UTC